Faruk Kilinc, Bahri Evren, Fethi Ahmet Ozdemir, Nevzat Gozel, Zafer Pekkolay, Erkan Cakmak

Is urotensin 2 levels related to disease progression in acromegaly

The study aimed to compare serum Urotensin-2 stages in the patients having active acromegaly with healthy individuals and to reveal and discuss the possible effects of UII on vascular changes in acromegaly patients. In this prospective, serum urotensin stages of 30 active acromegalic patients who are followed up in the experienced adult endocrinology center were compared with the serum urotensin stages of 30 healthy volunteers. Patients' IGF-1 along with GH were carefully measured by ECLIA method, and serum urotensin stages, by ELISA method. There was no variation between two groups comparing there age (p = 0.43). Patient group, mean GH was 6.60 ng / mL with mean IGF-1 stage of 355.2 ng / mL. The mean urotensin stage was 3.62±2.27 pmol / L in the acromegaly group, 4.82±2.87 pmol / L in the healthy control group. There was no significant positive correlation of urotensin with IGF-1 stages (r = 0.11, p>0.05). Similarly, the results did not display significant positive correlation urotensin stage with GH (r = 0.13, p>0.05). Serum urotensin-2 stage was lower in acromegaly patients compared to the healthy group (control) and this variation was not statistically significant.

PDF

___

1. Katznelson L, Laws ER Jr, Melmed S, et al. Endocrine society acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933-51.
2. Colao A, Pivonello R, Grasso LF, et al. Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study Eur J Endocrinol. 2011;165:713-21.
3. Colao A, Vitale G, Pivonello R, et al. Lombardi G. The heart: an end-organ of GH action. Eur J Endocrinol. 2004;151:93-101.
4. Dutta P, Das S, Bhansali A, et al. Congestive heart failure in acromegaly: A review of 6 cases. Indian J Endocrinol Metab. 2012;16:987-90.
5. Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am. 1992;21:597-614.
6. Gozu HI, Oztas D, Guleryuzlu Y, et al.Evaluation of cardiovascular parameters in acromegalic patients. Turk J Endocrinol Metab. 2007;11:1-6.
7. Vaudry H, Leprince J, Chatenet D, et al. International union of basic and clinical pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function. Pharmacol Rev. 2015;67:214-58.
8. Peng H, Zhang M, Cai X, et al. Association between human urotensin II and essential hypertension-a 1:1 matched case-control study. PLoS One. 2013; 8:1-6.
9. Buyukhatipoglu H, Buyukaslan H, Pehlivan Y, et al. Increased urotensin- II activity in patients with Raynaud’s phenomenon and systemic lupus erythematosus. Int J Rheum Dis. 2011;143:276-81.
10. Demirpence M, Guler A, Yilmaz H, , et al. Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly? J Endocrinol Invest. 2019;42:207-15.
11. Ong KL, Lam KS, Cheung BM Urotensin II: its function in health and its function in disease. Cardiovasc Drugs Ther. 2005;19:65-75.
12. Gruson D, Rousseau MF, Ketelslegers J-M ,et al. Raised plasma urotensin ii in type 2 diabetes patients is associated with the metabolic syndrome phenotype. J Clin Hypertension. 2010;12:653-60.
13. McDonald J, Batuwangala M, Lamber DG. Role of urotensin II and its receptor in health and disease. J Anesth. 2007;21:378-89.
14. Ong KL, Lam KS, Cheung BM. Urotensin II: its function in health and its function in disease. Cardiovasc Drugs Ther. 2005;19:65-75.
15. Gozel N, Oral K, Ozdemir FA, et al. An investigation of saliva and plasma levels of urotensin2 in recently diagnosed type 2 Diabetes mellitus patients on metformin treatment. Endokrynologia Polska. 2020;246-254:1-6.
16. Bousette N, Patel L, Douglas SA, et al. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis. 2004;176:117-23.
17. Babinska M, Holecki M, Prochaczek F, et al. Is plasma urotensin II concentration an indicator of myocardial damage in patients with acute coronary syndrome? Arch Med Sci. 2012;8:449-54.
18. Mosenkis A, Kallem RR, Danoff TM, et al. Renal impairment, hypertension and plasma urotensin II. Nephrol Dial Transplant. 2011;26: 609-14
19. Bottrill FE, Douglas SA, Hiley CR, and White R. Human urotensin-II is an endotheliumdependent vasodilator in rat small arteries, British J Pharmacol. 2000;130:1865-70.
20. Affolter JT, Newby DE, Wilkinson IB, et al. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. British J Clin Pharmacol. 2002;54:617-21.
21. Debiec R, Christofidou P, Denniff M. Urotensin-II system in genetic control of blood pressure and renal function. PLoS One. 2013;8:1-8.
22. Xie H, Wang X, He Y, et al. Association between Plasma Urotensin II and Risk of Hypertension: Findings from a Prospective Study. Int J Hypertension. 2020;1-6.
23. Zhang AY, Chen YF, Zhang DX. Urotensin II is a nitric oxide-dependent vasodilator andnatriuretic peptide in the rat kidney. Am J Physiol Renal Physiol. 2003;285:792-8.